Regarding leukemia, AML clones with IDH1 mutations seemed more sensitive to ABL1 kinase inhibitor ponatinib; conversely these with NRAS mutations were resistant to EGFR kinase inhibitor pelitinib [77]. This evidence concerns the gene ABL1 and acute myeloid leukemia.